Literature DB >> 15093539

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

Matthew C Franklin1, Kendall D Carey, Felix F Vajdos, Daniel J Leahy, Abraham M de Vos, Mark X Sliwkowski.   

Abstract

We have determined the 3.2 A X-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal antibody also known as 2C4 or Omnitarg. Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a binding pocket necessary for receptor dimerization and signaling. The ErbB2-pertuzumab structure, combined with earlier mutagenesis data, defines the pertuzumab residues essential for ErbB2 interaction. To analyze the ErbB2 side of the interface, we have mutated a number of residues contacting pertuzumab and examined the effects of these mutations on pertuzumab binding and ErbB2-ErbB3 heterodimerization. We have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensible for ErbB2-ErbB3 heterodimerization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093539     DOI: 10.1016/s1535-6108(04)00083-2

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  381 in total

1.  Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma.

Authors:  Hongliang Liu; Wei Liu; Bin Zhu; Qiang Xu; Xiaowei Ni; Ji Yu
Journal:  Mol Cell Biochem       Date:  2014-11-16       Impact factor: 3.396

2.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

3.  The peptide derived from erbB2 auto-inhibitor herstatin shared in the same epitope and function with functional antibody 2C4.

Authors:  Ming Lv; Chunxia Qiao; Nan Jiang; Xinying Li; Ming Yu; Chunmei Hou; Yan Li; Jiannan Feng; Beifen Shen
Journal:  Mol Biotechnol       Date:  2012-06       Impact factor: 2.695

Review 4.  Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.

Authors:  Brent N Rexer; Carlos L Arteaga
Journal:  Crit Rev Oncog       Date:  2012

5.  Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.

Authors:  Rui Wang; Lillian M Smyth; Neil Iyengar; Sarat Chandarlapaty; Shanu Modi; Maxine Jochelson; Sujata Patil; Larry Norton; Clifford A Hudis; Chau T Dang
Journal:  Oncologist       Date:  2019-01-02

Review 6.  Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.

Authors:  Ishwaria M Subbiah; Ana Maria Gonzalez-Angulo
Journal:  Curr Treat Options Oncol       Date:  2014-03

Review 7.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

8.  Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.

Authors:  Juan Felipe Franco-Gonzalez; Javier Ramos; Victor L Cruz; Javier Martínez-Salazar
Journal:  J Mol Model       Date:  2012-10-23       Impact factor: 1.810

Review 9.  Acquired Resistance to Drugs Targeting Tyrosine Kinases.

Authors:  Steven A Rosenzweig
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

Review 10.  Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Authors:  Zeynep Eroglu; Tomoko Tagawa; George Somlo
Journal:  Oncologist       Date:  2014-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.